Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review
Metrics: PDF 929 views | HTML 2326 views | ?
Li Yu1, Kefeng Li2 and Xiaoye Zhang1
1Department of Oncology, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China
2School of Medicine, University of California San Diego, San Diego, CA, USA
Xiaoye Zhang, email: firstname.lastname@example.org
Keywords: next-generation metabolomics; lung cancer; precision medicine; biomarker; pathogenesis
Received: May 24, 2017 Accepted: September 21, 2017 Published: November 11, 2017
Lung cancer is the leading cause of cancer-related death. Next-generation metabolomics is becoming a powerful emerging technology for studying the systems biology and chemistry of health and disease. This mini review summarized the main platforms of next-generation metabolomics and its main applications in lung cancer including early diagnosis, pathogenesis, classifications and precision medicine. The period covers between 2009 and August, 2017. The major issues and future directions of metabolomics in lung cancer research and clinical applications were also discussed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.